FULC Stock Price Forecast. Should You Buy FULC?
Stock Details
FULC 4
Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Andrew Fein·Fri Sep 13 2024
H.C. Wainwright
FULC 4
Fulcrum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Gregory Renza·Thu Sep 12 2024
RBC Capital
FULC 3
Fulcrum Therapeutics downgraded to Hold from Buy at Stifel
Dae Gon Ha downgraded Fulcrum Therapeutics·Thu Sep 12 2024
Stifel Nicolaus
FULC 2
BofA Securities Downgrades Fulcrum Therapeutics (FULC) to Underperform
Tazeen Ahmad·Thu Sep 12 2024
Bank of America Securities
FULC 10
BofA Securities Upgrades Fulcrum Therapeutics (FULC) to Neutral
Tazeen Ahmad·Mon Sep 09 2024
Bank of America Securities
FULC 15
Fulcrum Therapeutics (FULC) PT Raised to $15 at RBC Capital
Gregory Renza·Tue Sep 03 2024
RBC Capital
FULC 23
Cantor Fitzgerald Starts Fulcrum Therapeutics (FULC) at Overweight
Kristen Kluska·Mon May 20 2024
Cantor Fitzgerald
FULC 15
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) to Buy
Corinne Jenkins·Mon May 13 2024
Goldman Sachs
FULC 22
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
Dae Gon Ha·Mon May 13 2024
Stifel Nicolaus
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow